[1]符雨嫣孙辉王昊德王海银.抗肿瘤药品临床综合评价方法研究[J].中国卫生质量管理,2022,29(06):004-8.[doi:10.13912/j.cnki.chqm.2022.29.6.02 ]
　FU Yuyan,SUN Hui,WANG Haode.Clinical Comprehensive Evaluation Method of Anti-Tumor Drugs[J].Chinese Health Quality Management,2022,29(06):004-8.[doi:10.13912/j.cnki.chqm.2022.29.6.02 ]
点击复制

抗肿瘤药品临床综合评价方法研究
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第29卷
期数:
2022年06期
页码:
004-8
栏目:
特别关注
出版日期:
2022-06-28

文章信息/Info

Title:
Clinical Comprehensive Evaluation Method of Anti-Tumor Drugs
作者:
符雨嫣孙辉王昊德王海银
上海市卫生和健康发展研究中心
Author(s):
FU Yuyan; SUN Hui; WANG Haode
Shanghai Health Development Research Center
关键词:
药品临床综合评价; 指标体系; 抗肿瘤药品; 卫生技术评估; 多准则决策分析
Keywords:
Clinical Comprehensive Evaluation of Drugs;  Index System;  Anti-Tumor Drugs;  Health Technology Assessment; Multiple Criteria Decision Analysis
分类号:
R197.323；R979.1
DOI:
10.13912/j.cnki.chqm.2022.29.6.02
文献标志码:
A
摘要:
目的探索我国抗肿瘤药品临床综合评价方法，为准入决策和合理用药提供依据。方法以抗肿瘤药品为例，采用卫生技术评估与多准则决策分析相结合的方法，构建综合评价指标体系，确定评价流程。结果评价流程包括确定决策目标、构建评价指标体系、证据整合和分析、综合价值估计、结果可视化5个步骤。指标体系包括6个维度21个评价指标。以遴选晚期肝癌一线系统治疗药品为例，经综合评价，索拉非尼综合评分最高，经济性、可及性、适宜性优于仑伐替尼和FOLFOX4方案。结论卫生技术评估和多准则决策分析联合的方法可为药品临床综合评价提供方法学参考。
Abstract:
ObjectiveTo explore the clinical comprehensive evaluation method of anti-tumor medicine in China, and provides the basis for reasonable drug use and access decision.MethodsIn the case of anti-tumor medicine, the method of combining health technology assessment and multiple criteria decision analysis was adopted, and the comprehensive evaluation index system was constructed, and the evaluation process was determined.ResultsThe evaluation process included five steps: determining the decision objective, constructing the index system, integrating and analyzing the evidence, estimating the comprehensive value and visualizing the result. The index system included 6 dimensions and 21 evaluation indexes. Taking the selection of first-line systematic treatment drugs for advanced liver cancer as an example, after comprehensive evaluation, Sorafenib had the highest comprehensive score, and its economy, accessibility and suitability were better than Lenvatinib and FOLFOX4 scheme.Conclusion The combined method of health technology assessment and multiple criteria decision analysis can provide methodological reference for comprehensive clinical evaluation of drugs.

参考文献/References:

［1］国家卫生健康委员会办公厅. 药品临床综合评价管理指南（2021年版试行）［EB/OL］.（2021-07-28）［2021-07-30］. http：//www.nhc.gov.cn/yaozs/s2908/202 107/532e20800a47415d84adf3797b0f4869.shtml. ［2］GOETGHEBEUR MM , WAGNER M , KHOURY H , et al. Evidence and value: impact on DEcisionMaking–the EVIDEM framework and potential applications［J］.BMC Health Services Research, 2008, 8(1):270. ［3］ANGELIS A, KANAVOS P. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the advance value framework［J］.Social Science & Medicine, 2017, 188:137-156. ［4］Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017-2019［EB/OL］.(2020-01-31)［2022-03-21］. https://icer.org/our-approach/methods-process/value-assessment-framework/. ［5］SCHNIPPER LE, DAVIDSON NE, WOLLINS DS, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received［J］.Journal of Clinical Oncology，2016, 34(24):2925-2934. ［6］CHERNY N, SULLIVAN R, DAFNI U, et al.A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)［J］.Annals of Oncology,2015, 26(8):1547-1573. ［7］National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN Guidelines) with NCCN Evidence Blocks［EB/OL］.(2022-01-01)［2022-03-21］.https://www.nccn.org/evidenceblocks. ［8］戴泽琦，徐思敏，吴雪，等. EVIDEM 框架介绍及其在卫生决策中的应用［J/OL］.中国实验方剂学杂志,2022,28(4): 212-218. ［9］中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等.原发性肝癌的分层筛查与监测指南(2020版)［J］.肿瘤,2021,41(1):1-23.［10］国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）［J］.中华消化外科杂志，2020,19(1):1-20. ［11］MARSH K, IJZERMAN M, THOKALA P, et al. Multiple criteria decision analysis for health care decision Making—Emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force［J］.Value in Health:the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016,19(2):125-137. ［12］符雨嫣，金春林，孙辉，等. 晚期肝癌一线系统治疗药品的临床综合评价［J］.临床药物治疗杂志,2021,19(10):66-70. ［13］夏志远, 周萍, 刘亦悦,等. 国际新兴卫生技术评估经验及启示［J］.中国卫生质量管理, 2016, 23(1):91-95.

相似文献/References:

[1]刘晴,许苹,李世东,等.医疗风险预警指标体系构建研究[J].中国卫生质量管理,2016,23(04):030.[doi:10.13912/j.cnki.chqm.2016.23.3.11]
[2]丁慧,徐媛,郑克芬,等.社区卫生服务绩效评估指标体系构建研究[J].中国卫生质量管理,2016,23(04):113.[doi:10.13912/j.cnki.chqm.2016.23.3.36]
[3]姚远孙业勤张文一陈景元*.军队医院医疗质量与安全管理指标体系框架研究[J].中国卫生质量管理,2016,23(06):001.[doi:10.13912/j.cnki.chqm.2016.23.6.01]
[4]丁慧 陶诚.青岛市“健康城市”评价指标体系探讨[J].中国卫生质量管理,2016,23(06):093.[doi:10.13912/j.cnki.chqm.2016.23.6.31]
[5]许晨莹周易郭娜菲厉跃红庄薇.我国护理质量评价研究的文献计量学分析[J].中国卫生质量管理,2017,24(02):068.[doi:10.13912/j.cnki.chqm.2017.24.2.21]
[6]陈利娜张丽华.医院创新能力评价指标体系构建研究[J].中国卫生质量管理,2017,24(02):117.[doi:10.13912/j.cnki.chqm.2017.24.2.36]
[7]刘莉燕 李廷贵 彭瑞琴 左爱芳 石贞仙 何新梅 康凯宁.三级医院科室综合评价指标体系的构建[J].中国卫生质量管理,2018,25(04):053.[doi:10.13912/j.cnki.chqm.2018.25.4.17]
[8]王莹 王彤璐 赵娜 张艳丽 明敏馨 陈晓红.西藏自治区县级公立医院服务能力评价指标体系研究[J].中国卫生质量管理,2019,26(03):070.[doi:10.13912/j.cnki.chqm.2019.26.3.20]
[9]龚韩湘 林珮仪 江慧琳 李烁 伍宝玲 陈晓辉.应用Delphi-AHP法构建紧急医学救援能力评价指标体系[J].中国卫生质量管理,2019,26(05):136.[doi:10.13912/j.cnki.chqm.2019.26.5.38]
[10]赵琼姝 王志伟 赵博 郑博 梁頔 刘锦钰 李志刚 邰隽 谢向辉 倪鑫.儿童专科医院科室科技评价指标体系构建研究[J].中国卫生质量管理,2020,27(03):030.
　ZHAO Qiongshu,WANG Zhiwei,ZHAO Bo,et al.Construction of Science and Technology Evaluation Index System for Departments in Children's Specialized Hospital[J].Chinese Health Quality Management,2020,27(06):030.

更新日期/Last Update: 2022-06-28